Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
of treatment is to replace thyroid function but, in the latter condition, an additional aim is to keep the serum thyroid-stimulating hormone (TSH) at the lower limit of the normal range and possibly below (TSH suppressive therapy) to improve the
Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for other papers by Jasmin Asberger in
Google Scholar
PubMed
Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for other papers by Thalia Erbes in
Google Scholar
PubMed
Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for other papers by Markus Jaeger in
Google Scholar
PubMed
Search for other papers by Gerta Rücker in
Google Scholar
PubMed
Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for other papers by Claudia Nöthling in
Google Scholar
PubMed
Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for other papers by Andrea Ritter in
Google Scholar
PubMed
Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for other papers by Kai Berner in
Google Scholar
PubMed
Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for other papers by Ingolf Juhasz-Böss in
Google Scholar
PubMed
Faculty of Medicine, University of Freiburg, Freiburg, Germany
Institute of Veterinary Medicine, Georg-August-University Goettingen, Goettingen, Germany
Search for other papers by Marc Hirschfeld in
Google Scholar
PubMed
therapeutic options, these qualify for a successful approach of endocrine therapy ( 5 , 6 ). Endocrine therapy evolved as one of the main concepts in the adjuvant systemic treatment of hormone-positive breast cancer patients. Clinically established agents
Search for other papers by Ulla Schmidt in
Google Scholar
PubMed
Search for other papers by Birte Nygaard in
Google Scholar
PubMed
Search for other papers by Ebbe Winther Jensen in
Google Scholar
PubMed
Search for other papers by Jan Kvetny in
Google Scholar
PubMed
Search for other papers by Anne Jarløv in
Google Scholar
PubMed
Endocrine Unit, Department of Medicine, Endocrine Unit, Faculty of Health Sciences, Department of Medicine O, Herlev University Hospital, Herlev Ringvej, DK-2730 Herlev, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
calculated and was found to be similar before randomization (in median 80) and after T 4 monotherapy (78), whereas the ratio decreased remarkably (29) during combination therapy reflecting both decreasing FT 4 I and increasing FT 3 I. Table 2 Thyroid hormone
Search for other papers by Svjatoslavs Kistkins in
Google Scholar
PubMed
Search for other papers by Othmar Moser in
Google Scholar
PubMed
Search for other papers by Vitālijs Ankudovičs in
Google Scholar
PubMed
Search for other papers by Dmitrijs Blizņuks in
Google Scholar
PubMed
Search for other papers by Timurs Mihailovs in
Google Scholar
PubMed
Search for other papers by Sergejs Lobanovs in
Google Scholar
PubMed
Search for other papers by Harald Sourij in
Google Scholar
PubMed
Search for other papers by Andreas F H Pfeiffer in
Google Scholar
PubMed
Faculty of Medicine, University of Latvia, Riga, Latvia
Search for other papers by Valdis Pīrāgs in
Google Scholar
PubMed
perspectives in the combinatory use of incretin-based therapies in diabesity and physiological nature of hormonal crosstalk The primary objective of treating diabetes in particular novel pharmacological options leading to significant weight loss is to enhance
Search for other papers by Chan Sub Park in
Google Scholar
PubMed
Search for other papers by Jihye Choi in
Google Scholar
PubMed
Search for other papers by Min-Ki Seong in
Google Scholar
PubMed
Search for other papers by Sung-Eun Hong in
Google Scholar
PubMed
Search for other papers by Jae-Sung Kim in
Google Scholar
PubMed
Search for other papers by In-Chul Park in
Google Scholar
PubMed
Search for other papers by Hyesil Seol in
Google Scholar
PubMed
Search for other papers by Woo Chul Noh in
Google Scholar
PubMed
Search for other papers by Hyun-Ah Kim in
Google Scholar
PubMed
has a beneficial effect on reducing cerebrovascular events in healthy postmenopausal women. However, concerning the breast cancer, the excess exposure to the high level of estradiol such as has long-term hormone replacement therapy, early menarche
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Andreas F H Pfeiffer in
Google Scholar
PubMed
Search for other papers by Diego Ferone in
Google Scholar
PubMed
Search for other papers by Jens Sandahl Christiansen in
Google Scholar
PubMed
Search for other papers by David Gilfoyle in
Google Scholar
PubMed
Search for other papers by Eva Dam Christoffersen in
Google Scholar
PubMed
Search for other papers by Eva Mortensen in
Google Scholar
PubMed
Search for other papers by Jonathan A Leff in
Google Scholar
PubMed
Search for other papers by Michael Beckert in
Google Scholar
PubMed
and 70 years with a body mass index (BMI) of 19.0–36.0 kg/m 2 ) diagnosed with AGHD (defined according to the Growth Hormone Research Society Consensus Guidelines of 1998 and 2007) ( 1 , 12 ) who were stable on GH replacement therapy for at least 3
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Trine Holm Johannsen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jakob Albrethsen in
Google Scholar
PubMed
Search for other papers by Vassos Neocleous in
Google Scholar
PubMed
Search for other papers by Federico Baronio in
Google Scholar
PubMed
Search for other papers by Martine Cools in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Lise Aksglaede in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Niels Jørgensen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Peter Christiansen in
Google Scholar
PubMed
Pediatric Endocrinology Clinic, Department of Pediatrics, Aretaeio Hospital, Nicosia, Cyprus
Search for other papers by Meropi Toumba in
Google Scholar
PubMed
Search for other papers by Pavlos Fanis in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Marie Lindhardt Ljubicic in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Medicine, University of Copenhagen, Denmark
Search for other papers by Anders Juul in
Google Scholar
PubMed
adrenocorticotropic hormone and, thus, an overproduction of adrenal androgens, which may result in virilization, an altered growth pattern, and infertility ( 2 ). Treatment of CAH may comprise life-long replacement therapy with glucocorticoids and mineralocorticoids
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Bjarke R Medici in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Birte Nygaard in
Google Scholar
PubMed
Search for other papers by Jeppe L la Cour in
Google Scholar
PubMed
Department of Clinical Physiology and Nuclear Medicine, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Martin Krakauer in
Google Scholar
PubMed
Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Andreas Brønden in
Google Scholar
PubMed
Search for other papers by Mette P Sonne in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens J Holst in
Google Scholar
PubMed
Search for other papers by Jens F Rehfeld in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark
Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark
Search for other papers by Filip K Knop in
Google Scholar
PubMed
thyroid-stimulating hormone (TSH) (i.e. < 4 mU/L) (visit 2), and after at least 6 months of substitution therapy with TSH < 4 mU/L (visit 3). Levothyroxine therapy was initially evaluated every 4 weeks until the participants were euthyroid and then every 3
Search for other papers by Werner F Blum in
Google Scholar
PubMed
Search for other papers by Abdullah Alherbish in
Google Scholar
PubMed
Search for other papers by Afaf Alsagheir in
Google Scholar
PubMed
Search for other papers by Ahmed El Awwa in
Google Scholar
PubMed
Search for other papers by Walid Kaplan in
Google Scholar
PubMed
Search for other papers by Ekaterina Koledova in
Google Scholar
PubMed
Search for other papers by Martin O Savage in
Google Scholar
PubMed
Introduction The growth hormone (GH)–insulin-like growth factor (IGF)-I axis is the principle endocrine system regulating linear growth in children ( 1 ). Linked to the nutritional status of the individual, GH is a potent stimulator of IGF
Search for other papers by Thera P Links in
Google Scholar
PubMed
Search for other papers by Trynke van der Boom in
Google Scholar
PubMed
Search for other papers by Wouter T Zandee in
Google Scholar
PubMed
Search for other papers by Joop D Lefrandt in
Google Scholar
PubMed
Introduction Thyroid hormones and the cardiac system are closely related. This is illustrated by the fact that most characteristics and common symptoms of hyperthyroidism − such as palpitations, excitability, and perspiration − are the result